15 May 2018
According to IQVIA, in 2017, the Russian market of anti-tumor drugs was about 72 billion rubles in value terms and amounted to 14 million packages in physical terms. Compared to 2016, the sales of medicinal products in this segment increased by 10% in value terms and 19% in physical terms.
The analysis of market structure revealed differences in the supplies of Russian-made and foreign drugs to patients as, year after year, Russian-made medicines capture an increasingly larger share of procurement in the area of anti-tumor drugs. In 2017, they held 49% of the segment in physical terms and 36% in value terms. Sales of Russian-made anti-tumor drugs in 2017 reached 26 billion rubles (up 26% compared to 2016) in value terms or 6.7 million packages (up 12% compared to 2016) in physical terms.
Supplies of imported anti-tumor medicines for Russian patients are growing at a more moderate pace than the provision of locally made drugs. In 2017, their sales amounted to 6.9 million packages worth 46 billion rubles, which is up by 9% in value terms and 13% in physical terms compared to 2016. However, these figures are lower than those for procurement of Russian-made products and the segment as a whole. This trend indicates strengthening positions of Russian manufacturers in the market of anti-tumor drugs and successful implementation of import substitution program.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024